全球抗病毒药物市场规模、份额、趋势和成长分析报告（2026-2034年）

预计抗病毒药物市场规模将从 2025 年的 741.2 亿美元成长到 2034 年的 1,288.8 亿美元，2026 年至 2034 年的复合年增长率为 6.34%。

受病毒感染疾病不断增加以及对有效治疗方案持续需求的推动，全球抗病毒药物市场预计将迎来显着增长。随着流感、爱滋病和肝炎等新型病毒病原体的出现，全球对抗病毒药物的需求比以往任何时候都更加迫切。抗药性病毒株的出现进一步加剧了治疗选择的复杂性，促使製药公司加快对新型抗病毒药物研发的投资。这种对创新的重视有望透过推出应对现有和新出现的病毒威胁的新疗法来推动市场扩张。

此外，人们对医疗保健和疫苗接种重要性的认识不断提高，预计将推动抗病毒药物市场的发展。随着公共卫生政策强调接种疫苗预防病毒感染疾病的必要性，对用于辅助这些工作的抗病毒药物的需求将会增加。将抗病毒疗法与疫苗接种计划相结合，将有助于全面改善疾病管理和控制，尤其是在高风险族群中。此外，诸如新冠肺炎疫情等持续的全球卫生危机凸显了抗病毒研究的重要性，促使抗病毒药物的研发进程加快，并增加了相关研究经费。

此外，生物技术和个人化医疗的进步有望塑造抗病毒药物市场的未来。针对特定病毒作用机制和患者特征的标靶治疗正在研发中取得进展，有望提供更有效、更个人化的治疗方案。此外，联合治疗（将多种抗病毒药物合併使用以提高疗效并降低抗药性）的兴起正成为控制病毒感染疾病的关键策略。製药公司、研究机构和医疗服务提供者之间的合作对于推动这些创新至关重要，并确保抗病毒药物市场能够持续适应不断变化的病毒性疾病情况。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

4. 全球抗病毒药物市场（依药物类别划分）

• 市场分析、洞察与预测
• 核苷类似物
• 蛋白酶抑制剂
• 聚合酵素抑制剂
• 其他的

5. 全球抗病毒药物市场（按应用划分）

• 市场分析、洞察与预测
• HIV
• 肝炎
• 流感
• 疱疹
• 其他的

6. 全球抗病毒药物市场按分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

7. 全球抗病毒药物市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc
  • Johnson & Johnson
  • Roche Holding AG
  • Pfizer Inc
  • AstraZeneca Plc
  • Novartis AG
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy'S Laboratories Ltd

The Antiviral Drugs Market size is expected to reach USD 128.88 Billion in 2034 from USD 74.12 Billion (2025) growing at a CAGR of 6.34% during 2026-2034.

The global antiviral drugs market is set to witness substantial growth, driven by the increasing prevalence of viral infections and the ongoing need for effective therapeutic solutions. As the world faces the challenges posed by emerging viral pathogens, including influenza, HIV, and hepatitis, the demand for antiviral medications is more critical than ever. The rise of drug-resistant viral strains further complicates treatment options, prompting pharmaceutical companies to invest in research and development of novel antiviral agents. This focus on innovation is expected to propel market expansion, as new therapies are introduced to combat existing and emerging viral threats.

Moreover, the growing awareness of preventive healthcare and the importance of vaccination are set to bolster the antiviral drugs market. As public health initiatives emphasize the need for vaccination against viral infections, the demand for antiviral drugs that complement these efforts will increase. The integration of antiviral therapies with vaccination programs can enhance overall disease management and control, particularly in high-risk populations. Additionally, the ongoing global health crises, such as the COVID-19 pandemic, have underscored the importance of antiviral research, leading to accelerated development timelines and increased funding for antiviral drug discovery.

In addition, advancements in biotechnology and personalized medicine are expected to shape the future of the antiviral drugs market. The development of targeted therapies that address specific viral mechanisms and patient profiles is gaining traction, offering the potential for more effective and tailored treatment options. Furthermore, the rise of combination therapies that utilize multiple antiviral agents to enhance efficacy and reduce resistance is becoming a key strategy in managing viral infections. Collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers will be essential in driving these innovations, ensuring that the antiviral drugs market remains responsive to the evolving landscape of viral diseases.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Nucleoside Analogs
• Protease Inhibitors
• Polymerase Inhibitors
• Others

By Application

• HIV
• Hepatitis
• Influenza
• Herpes
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Gilead Sciences Inc, GlaxoSmithKline plc, BristolMyers Squibb Company, Merck Co Inc, Johnson Johnson, Roche Holding AG, Pfizer Inc, AstraZeneca plc, Novartis AG, Sanofi SA, Boehringer Ingelheim International GmbH, Mylan NV, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIVIRAL DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Nucleoside Analogs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Protease Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Polymerase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIVIRAL DRUGS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. HIV Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIVIRAL DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTIVIRAL DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Gilead Sciences Inc
  • 9.2.2 GlaxoSmithKline Plc
  • 9.2.3 Bristol-Myers Squibb Company
  • 9.2.4 Merck & Co. Inc
  • 9.2.5 Johnson & Johnson
  • 9.2.6 Roche Holding AG
  • 9.2.7 Pfizer Inc
  • 9.2.8 AstraZeneca Plc
  • 9.2.9 Novartis AG
  • 9.2.10 Sanofi S.A
  • 9.2.11 Boehringer Ingelheim International GmbH
  • 9.2.12 Mylan N.V
  • 9.2.13 Teva Pharmaceutical Industries Ltd
  • 9.2.14 Sun Pharmaceutical Industries Ltd
  • 9.2.15 Dr. Reddy'S Laboratories Ltd